Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 6/20 | 0.38 |
| ▸ | TTK | P33981 | 1/20 | 0.38 |
| ▸ | CLK1 | P49759 | 2/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | MET | P08581 | 2/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | MST1R | Q04912 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL723198 | 0.90 | EGLN1 (0.44) | EGLN1CLK1HDAC8MAPK1MET | |
| SCHEMBL296241 | 0.88 | EGLN1 (0.39) | EGLN1RETTTKCLK1HDAC8 | |
| SCHEMBL719766 | 0.83 | KDR (0.49) | EGLN1HDAC8MAPK1GSK3B | |
| SCHEMBL285300 | 0.77 | ALK (0.55) | PDPK1 | |
| SCHEMBL15257727 | 0.74 | RET (0.46) | RETTTKMAPK1GSK3BDYRK1A | |
| SCHEMBL719094 | 0.73 | GSK3B (0.43) | RETTTKMAPK1GSK3BDYRK1A | |
| SCHEMBL721257 | 0.73 | ALK (0.53) | PDPK1 | |
| SCHEMBL10104592 | 0.69 | MET (0.43) | EGLN1RETMAPK1METGSK3B | |
| SCHEMBL720700 | 0.69 | ALK (0.52) | PDPK1 | |
| SCHEMBL10104635 | 0.68 | ALK (0.50) | PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427461-B1 | 3-([1,2,3]TRIAZOL-4-YL)-PYRROLO[2,3-B]PYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-10-09 | — | — | EP | disclosed |
| US-8541584-B2 | 3-(1,2,3-triazol-4-yl) pyrrolo [2,3-b] pyridine derivatives | MERCK PATENT GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-8541584-B2 | 3-(1,2,3-triazol-4-yl) pyrrolo [2,3-b] pyridine derivatives | MERCK PATENT GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-8541584-B2 | 3-(1,2,3-triazol-4-yl) pyrrolo [2,3-b] pyridine derivatives | MERCK PATENT GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-20120053178-A1 | 3-(1,2,3-Triazol-4-yl) pyrrolo [2,3-b] pyridine derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-03-01 | — | — | US | disclosed |
| US-20120053178-A1 | 3-(1,2,3-Triazol-4-yl) pyrrolo [2,3-b] pyridine derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-03-01 | — | — | US | disclosed |
| US-20120053178-A1 | 3-(1,2,3-Triazol-4-yl) pyrrolo [2,3-b] pyridine derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-03-01 | — | — | US | disclosed |
| WO-2010127754-A1 | 3-([1,2,3]TRIAZOLE-4-YL)-PYRROLO[2,3-B]PYRIDINE DERIVATES | MERCK PATENT GMBH (DE) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053178-A1 | 3-(1,2,3-Triazol-4-yl) pyrrolo [2,3-b] pyridine derivatives | PDK1, PDK2, PDK3 | EGLN1 1168/4885RET 537/4885TTK 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.